Rockefeller Capital Management
PDSB icon

Rockefeller Capital Management’s PDS Biotechnology PDSB Stock Holding History

Rockefeller Capital Management’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$22.3K Buy
29,664
+2,000
+7% +$1.14K ﹤0.01% 3853
2026
Q2 		$24.4K Hold
27,664
– – ﹤0.01% 3675
2026
Q1 		$16.7K Buy
27,664
+2,000
+8% +$1.5K ﹤0.01% 3784
2025
Q4 		$19.8K Sell
25,664
-8,803
-26% -$7.94K ﹤0.01% 3521
2025
Q3 		$34.8K Buy
+34,467
New +$40.5K ﹤0.01% 3086
2023
Q1 		– Sell
-3,413
Closed -$45K – 3339
2022
Q4 		$45K Buy
+3,413
New +$24.1K ﹤0.01% 2440
2022
Q2 		– Sell
-955
Closed -$5K – 4323
2022
Q1 		$5K Sell
955
-5,730
-86% -$35.6K ﹤0.01% 3347
2021
Q4 		$54K Hold
6,685
– – ﹤0.01% 2185
2021
Q3 		$99K Hold
6,685
– – ﹤0.01% 1866
2021
Q2 		$83K Buy
+6,685
New +$52.2K ﹤0.01% 1875

Other funds holding PDSB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Militia Capital Management
Militia Capital Management Austin, Texas $4B AUM
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $96.6B AUM 22.52% 1-Year Est. Return
Quantinno Capital Management
Quantinno Capital Management New York $106B AUM 29.93% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
William Blair & Company
William Blair & Company Chicago, Illinois $38.6B AUM 22.09% 1-Year Est. Return

Rockefeller Capital Management's PDSB Position: Q3 2026 in Review

Rockefeller Capital Management increased its PDS Biotechnology (PDSB) stake by 7.2% in Q3 2026, buying an estimated $1.14K and bringing the position to 29,664 shares worth $22.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3853.

Rockefeller Capital Management first reported a position in PDSB in Q2 2021 and has held it in 10 quarters since. The position peaked at $99K in Q3 2021. 48 funds tracked by Wall St. Rank hold PDSB as of Q3 2026.

  • Rockefeller Capital Management held 29,664 shares of PDS Biotechnology worth $22.3K as of Q3 2026.
  • Rockefeller Capital Management bought 2,000 PDS Biotechnology shares in Q3 2026, an estimated $1.14K.
  • PDS Biotechnology made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #3853 holding.
  • Rockefeller Capital Management first reported a position in PDS Biotechnology in Q2 2021 and has held it in 10 quarters since.
  • Rockefeller Capital Management's PDS Biotechnology position peaked at $99K in Q3 2021.
  • 48 funds tracked by Wall St. Rank held PDS Biotechnology as of Q3 2026.

Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.